Vedolizumab

Definition: Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. source: Wikipedia

ID

704256006

ID date

2 Apr 2015

Previous ID

24540711000001103

Name

Vedolizumab